Endocardial ablation of ganglionated plexus for the treatment of carotid sinus syndrome

Carlos Minguito‐Carazo,Jesús Daniel Martínez‐Alday,Javier García Seara,José Luis Martínez‐Sande,Teba González‐Ferrero,Oleksandr Shangutov,Juliana Elices‐Teja,X. Alberte Fernández López,José Ramón González‐Juanatey,Moisés Rodríguez‐Mañero
DOI: https://doi.org/10.1111/jce.16469
IF: 2.7
2024-10-18
Journal of Cardiovascular Electrophysiology
Abstract:Cardioneuroablation for the management of carotid sinus syndrome. Cardioneuroablation could be a reasonable alternative to pacemaker implantation in symptomatic carotid sinus syndrome. CSS, carotid sinus syndrome; CSM, carotid sinus massage; HR, heart rate; SF‐36 QLQ, SF‐36 quality‐of‐life questionnaire. Introduction Carotid sinus syndrome (CSS), characterized by exaggerated vagal responses leading to asystolic pauses with carotid sinus massage (CSM), often necessitates pacemaker implantation. This study investigates cardioneuroablation (CNA) as an alternative strategy for CSS. Methods Prospective study of consecutive patients referred for CNA due to CSS. All patients underwent CSM, atropine test and 24‐h Holter monitoring before the procedure and at 6 months. The primary objective was the absence of any cardioinhibitory response to CSM following CNA. Secondary objectives included the combined endpoint of syncope and presyncope‐free survival, pacemaker‐free survival, differences in heart rate variation (HRV), as well as differences in the pre‐ and postprocedure atropine tests and in the SF‐36 quality‐of‐life questionnaire. Results A total of 13 consecutive patients (84.6% male, mean age 63.8 ± 12.3 years) were included. CSM revealed a symptomatic asystolic pause in all patients before CNA (7.3 [5.6–10.5] s). After the procedure, all the patients had a negative CSM, and only one patient (7.7%) had a positive CSM at 6 months. After a median follow‐up of 11.2 (10.6–16.3) months, syncope or presyncope‐free survival was 84.6%, and none required pacemaker implantation. There was an improvement in the energy and health change items in the SF‐36 questionnaire. There was a reduction in HR increase in the atropine test at 6 months (pre‐CNA: 66% [52–84] vs. post‐CNA 26.0% (19.8–29.3]; p = .008) and in HRV parameters. Conclusions In this proof‐of‐efficacy study, performed in patients affected by asystolic CSS, CNA was effective in reducing the rate of cardioinhibitory responses, suggesting a potential efficacy in also reducing syncopal recurrences. Controlled trials are warranted to corroborate clinical findings.
cardiac & cardiovascular systems
What problem does this paper attempt to address?